OBJECTIVE: The overall aims of the ADDITION study are to evaluate whether screening for prevalent undiagnosed Type 2 diabetes is feasible, and whether subsequent optimised intensive treatment of diabetes, and associated risk factors, is feasible and beneficial. DESIGN: Population-based screening in three European countries followed by an open, randomised controlled trial. SUBJECTS AND METHODS: People aged 40-69 y in the community, without known diabetes, will be offered a random capillary blood glucose screening test by their primary care physicians, followed, if equal to or greater than 5.5 mmol/l, by fasting and 2-h post-glucose-challenge blood glucose measurements. Three thousand newly diagnosed patients will subsequently receive conventional treatment (according to current national guidelines) or intensive multifactorial treatment (lifestyle advice, prescription of aspirin and ACE-inhibitors, in addition to protocol-driven tight control of blood glucose, blood pressure and cholesterol). Patients allocated to intensive treatment will be further randomised to centre-specific interventions to motivate adherence to lifestyle changes and medication. Duration of follow-up is planned for 5 y. Endpoints will include mortality, macrovascular and microvascular complications, patient health status and satisfaction, process-of-care indicators and costs.
RCT Entities:
OBJECTIVE: The overall aims of the ADDITION study are to evaluate whether screening for prevalent undiagnosed Type 2 diabetes is feasible, and whether subsequent optimised intensive treatment of diabetes, and associated risk factors, is feasible and beneficial. DESIGN: Population-based screening in three European countries followed by an open, randomised controlled trial. SUBJECTS AND METHODS: People aged 40-69 y in the community, without known diabetes, will be offered a random capillary blood glucose screening test by their primary care physicians, followed, if equal to or greater than 5.5 mmol/l, by fasting and 2-h post-glucose-challenge blood glucose measurements. Three thousand newly diagnosed patients will subsequently receive conventional treatment (according to current national guidelines) or intensive multifactorial treatment (lifestyle advice, prescription of aspirin and ACE-inhibitors, in addition to protocol-driven tight control of blood glucose, blood pressure and cholesterol). Patients allocated to intensive treatment will be further randomised to centre-specific interventions to motivate adherence to lifestyle changes and medication. Duration of follow-up is planned for 5 y. Endpoints will include mortality, macrovascular and microvascular complications, patient health status and satisfaction, process-of-care indicators and costs.
Authors: D R Webb; L J Gray; K Khunti; B Srinivasan; N Taub; S Campbell; J Barnett; A Farooqi; J B Echouffo-Tcheugui; S J Griffin; N J Wareham; M J Davies Journal: Diabetologia Date: 2011-06-03 Impact factor: 10.122
Authors: Mohammed K Ali; Kavita Singh; Dimple Kondal; Raji Devarajan; Shivani A Patel; Roopa Shivashankar; Vamadevan S Ajay; A G Unnikrishnan; V Usha Menon; Premlata K Varthakavi; Vijay Viswanathan; Mala Dharmalingam; Ganapati Bantwal; Rakesh Kumar Sahay; Muhammad Qamar Masood; Rajesh Khadgawat; Ankush Desai; Bipin Sethi; Dorairaj Prabhakaran; K M Venkat Narayan; Nikhil Tandon Journal: Ann Intern Med Date: 2016-07-12 Impact factor: 25.391
Authors: T Sparsø; G Andersen; T Nielsen; K S Burgdorf; A P Gjesing; A L Nielsen; A Albrechtsen; S S Rasmussen; T Jørgensen; K Borch-Johnsen; A Sandbaek; T Lauritzen; S Madsbad; T Hansen; O Pedersen Journal: Diabetologia Date: 2007-11-16 Impact factor: 10.122
Authors: T Sparsø; G Andersen; A Albrechtsen; T Jørgensen; K Borch-Johnsen; A Sandbaek; T Lauritzen; J Wasson; M A Permutt; B Glaser; S Madsbad; O Pedersen; T Hansen Journal: Diabetologia Date: 2008-06-21 Impact factor: 10.122